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Adipose tissue (AT) secretes several adipokines that
influence insulin sensitivity and potentially link obe-
sity to insulin resistance. Apelin, a peptide present
in different tissues, is also secreted by adipocytes.
Apelin is upregulated in obese and hyperinsulinemic
humans and mice. Although a tight relation exists be-
tween the regulation of apelin and insulin, it remains
largely unknown whether apelin affects whole-body
glucose utilization. Herein, we show that in chow-
fed mice, acute intravenous injection of apelin has
a powerful glucose-lowering effect associated with
enhanced glucose utilization in skeletal muscle and
AT. Through in vivo and in vitro pharmacological
and genetic approaches, we demonstrate the in-
volvement of endothelial NO synthase, AMP-acti-
vated protein kinase, and Akt in apelin-stimulated
glucose uptake in soleus muscle. Remarkably, in
obese and insulin-resistant mice, apelin restored glu-
cose tolerance and increased glucose utilization.
Apelin could thus represent a promising target in
the management of insulin resistance.
INTRODUCTION
Adipose tissue (AT) represents a major endocrine organ produc-
ing a variety of factors (adipokines) affecting insulin sensitivity
and energy balance (Rosen and Spiegelman, 2006). Excess of
AT in obesity induces modifications of adipokine levels known
to play major roles in modulating obesity-related disorders such
as type 2 diabetes or cardiovascular diseases (Mlinar et al.,
2007). Adipocytes have recently been demonstrated to synthe-
size and secrete apelin, a bioactive peptide (Boucher et al.,
2005). Apelin is also present in other tissues and in the blood-
stream. It derives from a 77 amino acid precursor, processed
into several active molecular forms such as apelin-13 (Carpe´ne´
et al., 2007). Apelin is the endogenous ligand of the G protein-
coupled receptor, APJ (Tatemoto et al., 1998). Apelin and APJ
mRNA are widely expressed in mammal tissues and are associ-
ated with functional effects in both the central nervous system
and peripheral tissues (Carpe´ne´ et al., 2007).Cell MDifferent studies also pointed out an emerging role of apelin in
energy metabolism. A central administration of apelin was
shown to reduce food intake in rat, but contrasting effects
were also reported (Carpe´ne´ et al., 2007; Valle et al., 2008).
Our group showed that apelin serum levels are related to the
nutritional status and parallel insulin plasma levels in mice and
humans (Boucher et al., 2005; Castan-Laurell et al., 2008). Fur-
thermore, apelin plasma concentrations are increased in obese
(Heinonen et al., 2005) and type 2 diabetic subjects (Li et al.,
2006) as well as in hyperinsulinemic obese mice (Boucher
et al., 2005). In mice, apelin inhibited glucose-stimulated insulin
secretion in pancreatic islets (So¨rhede Winzell et al., 2005), sug-
gesting a link with glucose homeostasis. Recently, a 14 day ape-
lin treatment in mice was shown to regulate adiposity and to in-
crease uncoupling proteins expression (Higuchi et al., 2007),
accounting for a role of apelin in energy metabolism.
Since plasma apelin concentrations correlate with insulinemia,
similarities between apelin and insulin functions were hypothe-
sized. The potential role of apelin in whole-body glucose
disposal in normal and insulin-resistant mice remains largely
unknown. In this context, our data show that, in normal mice,
acute i.v. injection of apelin has a powerful glucose-lowering ef-
fect. Apelin stimulates glucose uptake in soleus muscle by endo-
thelial nitric oxide synthase- (eNOS), AMP-activated protein ki-
nase- (AMPK), and Akt-dependent pathways. In obese and
insulin-resistant mice, apelin also improves glucose uptake in
insulin-sensitive tissues underlying a relevant role of apelin in
glucose metabolism.
RESULTS
Effect of Apelin on Glycemia and Glucose Utilization
A bolus of increasing concentrations of apelin was i.v. injected in
mice every 45 min, and blood glucose levels were measured
(Figure 1A). When compared to vehicle, a significant reduction
of glycemia was observed at each time point measured after
an injection of 200 pmol/kg apelin. Higher doses decreased gly-
cemia but failed to promote a stronger effect. At the end of the
experiment, apelin induced a 25% decrease in blood glucose
from 1.18 ± 0.04 g/l (time 0) to 0.89 ± 0.05 g/l (time 225 min). Dur-
ing a single injection of 200 pmol/kg apelin, a significant de-
crease of glycemia was also obtained during 60 min (not shown).
During an oral glucose tolerance test (OGTT) (Figure 1B), the
amplitude of the hyperglycemic response was significantlyetabolism 8, 437–445, November 5, 2008 ª2008 Elsevier Inc. 437
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Apelin Stimulates Glucose UtilizationFigure 1. Apelin Decreases Glycemia and Stimulates Glucose Turnover and Utilization in WT Mice
(A) Effect of various apelin doses (A, 40 pmol/kg; B, 100 pmol/kg; C, 200 pmol/kg; D, 1000 pmol/kg; E, 2000 pmol/kg) i.v. injected every 45 min on blood glucose
(black circles) compared to PBS-injected mice (white circles). Results are the mean ± SEM of five mice per group. *p < 0.05, **p < 0.01.
(B) OGTT in 6-hr-fasted mice i.v. injected with either PBS (white circles) or 200 pmol/kg apelin (black circles). Results are the mean ± SEM of six mice per group.
*p < 0.05, ***p < 0.005 versus control.
(C) Glucose turnover (TO) and associated glycolysis and glycogen synthesis (Gln Synt) rates in basal conditions and during an euglycemic-hyperinsulinemic
clamp in control (white bars) and apelin-infused (75 pmol/kg/min) mice (black bars). The results are the mean ± SEM of five mice per group. *p < 0.05, ***p < 0.005.
(D) Tissue glucose utilization during an euglycemic-hyperinsulinemic clamp in PBS- (white bars) and apelin-infused (75 pmol/kg/min) mice (black bars). The
results are the mean ± SEM of five mice per group. *p < 0.05 versus saline.
(E) Quantification of APJ mRNA by real-time PCR in different tissues. Results are the mean ± SEM; n = 5.
(F) Glucose uptake measured in isolated soleus muscles incubated with apelin and/or insulin at the indicated concentrations. Values are the mean ± SEM; n = 5–9.
*p < 0.05, ** p < 0.01 versus basal, p < 0.05 versus 100 nM insulin.weaker in 200 pmol/kg apelin- compared to vehicle-injected
mice. Plasma insulin levels were similar in control and apelin-
injected mice (Figure S1) suggesting that, in these conditions,
apelin had no effect on insulin secretion. Apelin plasma levels
measured before OGTT and 15 min after glucose load were
not modified (Table S1).
The influence of apelin on whole-body glucose utilization was
then determined in conscious mice under basal conditions and
during an euglycemic-hyperinsulinemic clamp (Figure 1C). In438 Cell Metabolism 8, 437–445, November 5, 2008 ª2008 Elsevierbasal state, apelin infusion (75 pmol/kg/min) significantly in-
creased glucose turnover (TO) and, hence, hepatic glucose pro-
duction adapted to maintain euglycemia. Apelin also increased
whole-body glucose TO in hyperinsulinemic conditions by stim-
ulating whole-body glycolysis and glycogen synthesis rates.
Hepatic glucose output (HGO) during clamp conditions was in-
hibited in the absence or presence of apelin (0.57 ± 2.1 versus
0.8 ± 3.2 mg/kg/min, respectively; n = 5). The tissues responsible
for apelin-mediated increase in glucose utilization were white ATInc.
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Apelin Stimulates Glucose Utilization(WAT) and skeletal muscles (soleus and extensor digitorum lon-
gus [EDL]) (Figure 1D). During the clamp, apelin infusion resulted
in a physiological increase of apelinemia (maximal 2.2-fold in-
crease) that was not influenced by hyperinsulinemia (Table S1).
In order to determine whether apelin exerts a direct effect on
glucose uptake, we studied the in vitro effect of apelin in soleus
muscle that express the apelin receptor (Figure 1E). Of note, APJ
was not expressed in liver. Apelin stimulated glucose uptake in
soleus muscle in a dose-dependent manner with a significant ef-
fect at 10 nM (Figure 1F). In addition, apelin (1 mM) was able to
increase maximal insulin-stimulated glucose transport, suggest-
ing that their effects can be additive and mediated by different
mechanisms.
Apelin Signaling Involved in Muscle Glucose Uptake
Glucose transport can be stimulated via a NO-dependent path-
way (Roy et al., 1998; Higaki et al., 2001). Since it has been
shown that apelin activates eNOS in endothelial cells (Tatemoto
et al., 2001), we first checked whether apelin was able to phos-
phorylate eNOS in vitro in soleus muscle. Time-course studies
revealed that phosphorylation of eNOS was significantly in-
creased at 10 min, and this effect was dose dependent
(Figure 2A). In vivo, apelin also induced a significant phosphory-
lation of eNOS in soleus muscle (Figure 2B). In addition, the same
injection of apelin did not modify the mean blood pressure and
plasma NO metabolites (not shown). The importance of eNOS
in apelin effect was then investigated in eNOS deficient
(eNOS/) mice. During an euglycemic-hyperinsulinemic
clamp, apelin infusion failed to increase the glucose infusion
rate (GIR) (Figure 2C) and glucose utilization in WAT and muscles
(Figure 2D). In vitro, 10 nM and 1 mM apelin also failed to stimu-
late glucose transport in soleus muscle isolated from eNOS/
mice, whereas insulin effect was maintained (Figure 2E).
We studied AMPK as a potential upstream target of eNOS-me-
diated stimulation of glucose transport (Barnes and Zierath,
2005). Time-course studies in isolated soleus muscle revealed
that apelin induced in parallel the phosphorylation of AMPK
and acetyl-CoA carboxylase (ACC), its downstream target en-
zyme, at 20 until 60 min (Figure 3A). Moreover, apelin-stimulated
phosphorylation of AMPK and ACC in soleus muscle was dose
dependent with a significant effect at 10 nM (Figure 3A). A signif-
icant increase of AMPK and ACC phosphorylation was also
observed in vivo in soleus muscle (Figure 3B). The involvement
of AMPK in apelin-stimulated glucose transport was confirmed
first in vitro by the use of C compound, a selective AMPK inhib-
itor. C Compound (20 mM) completely prevented apelin-induced
AMPK phosphorylation and glucose uptake in soleus muscle
(Figure 3C). Second, we performed euglycemic-hyperinsuline-
mic clamp studies in mice deficient in AMPK activity specifi-
cally in muscle (DN AMPK) (Mu et al., 2003) and WT mice per-
fused with apelin or saline. The GIR between saline-injected
WT and DN-AMPK mice was similar (64.4 ± 9.3 versus 61.7 ±
9.3 mg /kg/ min; n = 3). The GIR was significantly increased in
apelin-injected WT mice but not in DN-AMPK mice (88. 4 ± 2.3
versus 77.3 ± 6.8 mg /kg/ min; n = 6). Moreover, in apelin-
infused DN-AMPK mice, apelin did not increase glucose utiliza-
tion in muscles (EDL and soleus) compared to apelin-infused
WT mice. However, apelin still increased it in WAT where AMPK
is still active (Figure 3D).CellIn order to know whether apelin interacts with insulin signaling
pathway, we studied the effect of apelin on Akt phosphorylation.
In vitro time-course study in soleus muscle indicated that maxi-
mal phosphorylation by 1 mM apelin was attained at 30 min, and
this effect was dose dependent (Figure 3E). In vivo, in the same
conditions used to study AMPK phosphorylation, apelin also
phosphorylated Akt in soleus muscle (not shown). Apelin-
induced glucose transport measured in the presence of 25 mM
LY294002, a specific inhibitor of PI3-kinase, was completely
suppressed (Figure 3F). Finally, the relative position of the differ-
ent candidates in the signaling cascade was studied (Figure 3G).
In soleus muscle of DN AMPK, Akt, and eNOS were not phos-
phorylated by 10 nM apelin. Furthermore, LY294002 did not in-
hibit the phosphorylation of AMPK by10 nM apelin in soleus mus-
cle of WT mice whereas it inhibited Akt phosphorylation. In vivo in
soleus muscle of eNOS/ mice, both AMPK and Akt were still
phosphorylated 20 min after apelin injection. All together these
data suggest that AMPK was upstream eNOS and Akt.
Apelin Improves In Vivo Glucose Utilization
in Insulin-Resistant Mice
High fat (HF)-fed C57Bl6/J mice displaying hyperinsulinemia, hy-
perglycemia, and obesity (not shown) were subjected to an
OGTT. HF-fed mice were largely glucose intolerant (Figure 4A).
However, in apelin-injected mice, glucose tolerance was signifi-
cantly improved. Fifteen minutes after oral glucose intake, insulin
plasma levels were similar in control (12.15 ± 1.10 ng/ml) and in
apelin-injected mice (11.94 ± 1.44 ng/ml). Apelin plasma levels
were not significantly modified during the experiment (Table
S1) but basal levels were increased compared to chow-fed
mice (2.26 ± 0.31 versus 0.97 ± 0.09 ng/ml p < 0.005).
Apelin significantly increased basal glucose TO in insulin-
resistant mice (Figure 4B) without affecting the mean blood glu-
cose concentration (5.13 ± 0.69 and 5.06 ± 0.47 mM in PBS- and
apelin-infused mice, respectively; n = 6). Thus apelin directly in-
creased peripheral glucose utilization. Consequently, HGO was
adapted. During euglycemic-hyperinsulinemic clamp, HGO
was also inhibited in the presence of apelin (4.6 ± 3.7 versus
3.5 ± 2.2 mg/kg/min; n = 6). Insulin-resistant mice exhibited
a largely blunted insulin response but apelin infusion significantly
increased the GIR (Figure 4C) and glucose utilization in not only
WAT, soleus, and EDL muscles but also in heart (Figure 4D).
DISCUSSION
Glucose homeostasis depends upon a balance between HGO
and glucose utilization by insulin-sensitive (AT, skeletal muscle)
and insulin-insensitive tissues. The present study shows, for
the first time, that apelin, administered in a physiological range,
improves in vivo glucose metabolism in normal and insulin-resis-
tant HF-fed mice by increasing glucose utilization in insulin-sen-
sitive tissues rather than HGO inhibition. In HF-fed mice, the liver
becomes rapidly insulin resistant and thus HGO is not necessar-
ily inhibited (Samuel et al., 2004). However, in our experimental
conditions, the clamp procedure (high insulin levels) induced
a complete suppression of HGO in both chow- and HF-fed
mice as previously reported (Cani et al., 2007). By performing
glucose TO measurements in a basal state in HF-fed mice, we
showed that apelin directly increased peripheral glucoseMetabolism 8, 437–445, November 5, 2008 ª2008 Elsevier Inc. 439
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Apelin Stimulates Glucose UtilizationFigure 2. Apelin Effect on Glucose Utilization Is eNOS Dependent
(A) Representative blot of in vitro time-course study of eNOS phosphorylation in soleus muscles by apelin (1 mM) and dose response at the indicated apelin con-
centrations (incubation time with apelin: 20 min). The graph shows the quantified data; n = 3. *p < 0.05, **p < 0.01.
(B) In vivo eNOS phosphorylation in soleus muscle 20 min after an iv injection of 200 pmol/kg apelin or PBS (control) in 6-hr-fasted mice.
(C and D) Measure of GIR (C) and tissue glucose utilization (D) during an euglycemic-hyperinsulinemic clamp in apelin- (gray bars) and saline-infused (hatched
bars) control mice and in apelin- (black bars) and saline-infused (white bars) eNOS/ mice. The results are the mean ± SEM of four mice per group and per
tissue. *p < 0.05, **p < 0.01.
(E) Effect of apelin and insulin on glucose uptake in soleus muscle isolated from eNOS/ mice. The results are the mean ± SEM; n = 4. *p < 0.05 versus basal.utilization through a most likely insulin-independent manner.
Hence, HGO secondarily adapted to maintain euglycemia. The
primary effect of apelin cannot target the liver during basal glu-
cose TO experiment since there are no APJ receptors present
and no change in blood glucose or insulin concentrations. How-
ever, the whole-body improvement of insulin action could have
secondarily improved hepatic glucose metabolism.
In chow-fed mice, acute administration of physiological con-
centrations of apelin exerts a substantial glucose-lowering effect
in both basal and insulin-stimulated conditions. So¨rhede Winzell440 Cell Metabolism 8, 437–445, November 5, 2008 ª2008 Elsevieret al. (2005) reported that apelin had no effect on basal levels of
glucose. This discrepancy could be due to the fact that, in their
experiments, mice were anesthetized or that apelin-36 was
used instead of apelin-13. Several endogenous fragments of
physiologically active apelin have been described in tissues
and blood (Carpe´ne´ et al., 2007). Apelin-13 and apelin-36 could
have different effects or promote a differential desensitization
pattern that may be important for their respective physiological
roles as previously described (Masri et al., 2006). In the present








Apelin Stimulates Glucose Utilizationfound between apelin- and PBS-injected mice during OGTT. In-
creased glucose turnover or decreased glycemia with no change
of insulin plasma levels has also been described for leptin (Ka-
mohara et al., 1997). Apelin effect might be either a direct action
on glucose utilizing tissues or the result of an increased insulin
sensitivity.
Hemodynamic factors have been suggested to be associated
with glucose utilization. Vasodilatation is associated with en-
hanced insulin sensitivity, whereas vasoconstriction results in
decreased glucose utilization (Juan et al., 2005). Apelin was
shown to cause endothelium-dependent vasodilatation by trig-
gering the release of NO (Tatemoto et al., 2001). The absence
of apelin effect in vivo in eNOS/ mice could result from
a crosstalk between hemodynamic and direct metabolic effect
of apelin on glucose uptake. The fact that apelin stimulates
NO-dependent modifications of blood flow cannot be excluded
as reported for insulin (Duplain et al., 2001). Alternatively, NO
may act on apelin-stimulated glucose uptake, independently of
its vascular action since eNOS is expressed in skeletal muscle
(Kapur et al., 1997). This is further supported by the experiments
performed in vitro in soleus muscle in the absence of confound-
ing effects of blood flow. Indeed, apelin stimulates both eNOS
phosphorylation and glucose uptake in soleus muscle of WT
mice, and this effect is completely suppressed in eNOS/
mice. All together these data indicate that eNOS activation is
essential for apelin to exert its effect on glucose uptake.
Several studies have shown that AMPK is a possible upstream
mediator of NO signaling (Fryer et al., 2000; Li et al., 2004). AMPK
plays a pivotal role in the regulation of skeletal muscle glucose
and fatty acid metabolism (Long and Zierath, 2006). Li et al.
(2004) described the role of the NO pathway in AMPK-mediated
glucose uptake in heart. Here, we provided evidence, for the first
time, that apelin increases in parallel phosphorylation of AMPK
and ACC in soleus skeletal muscle both in vivo and in vitro. Fur-
thermore, AMPK is necessary to mediate the systemic action of
apelin on glucose metabolism since during clamp studies in DN-
AMPK mice, the apelin-stimulated glucose utilization in muscles
was suppressed. However, apelin stimulates also glucose up-
take by a mechanism dependent of insulin pathway. We showed,
in the present study, that apelin interacts with insulin signaling at
the level of PI3K/Akt. Apelin is known to phosphorylate Akt in
other cell types (Carpe´ne´ et al., 2007). In addition, by combining
different experiments targeting one by one the signaling mole-
cules involved, we demonstrated that AMPK is upstream Akt
and eNOS. However, we do not know whether Akt is an interme-
diate between AMPK and eNOS or acts in parallel to modulate
the activation eNOS by apelin.
Improvement of insulin sensitivity and reduction of blood glu-
cose levels are expected goals for the treatment of type 2 diabe-
tes. Remarkably, we demonstrated that acute injection of apelin
was able to improve glucose tolerance in HF-induced insulin-re-
sistant mice and to increase glucose utilization in WAT, skeletal
muscles, and heart. The increased glucose uptake in heart was
unexpected, since it was not observed in chow-fed mice. Since
glucose utilization in heart of chow-fed saline-injected mice ap-
pears maximal, the apelin effect might not be additive. Con-
versely, in insulin-resistant mice, apelin could ameliorate the
defective glucose utilization in heart; this noticeable effect needs
to be further depicted. Hence, apelin has a sustained effect onCell Mglucose utilization in insulin-resistant mice. Chronic apelin treat-
ment will provide better insights into the tonic role of apelin in
insulin-resistant mice. Higuchi et al. (2007) already observed im-
provement of GTT in WT mice after 14 day apelin treatment. We
also found a significant amelioration of OGTT in HF-fed obese
mice (not shown). Thus, apelin appears to be a promising too
in the treatment of type 2 diabetes.
In obese and hyperinsulinemic mice, we previously reported
higher levels of blood apelin than in control (Boucher et al.,
2005). It could be hypothesized that the high levels of circulating
apelin found in obese help to delay the onset of insulin resis-
tance. Over time, the endogenous apelin might be either insuffi-
cient or inefficient. Apelin peptides are subjected to enzymatic
degradation leading to inactive forms of apelin (Carpe´ne´ et al.,
2007). These inactive forms cannot be discriminated from the
active ones in the assay used. Very recently, Valle et al. (2008
demonstrated that in vitro, apelin-13 was progressively con-
verted to [Pyr1] apelin and no other breakdown products were
found. Another hypothesis is that the high levels of apelin lead
to apelin resistance. However, Zhong et al. (2007) showed that
even if there is a depressed expression of apelin receptor in
aortic rings of diabetic mice, apelin enhanced phosphorylation
of eNOS and Akt. Thus, the apelin-mediated biological effects
observed herein in insulin-resistant mice might be due to the
added exogenous active form of apelin-13 in the bloodstream.
In conclusion, the present study reveals apelin as a new endo-
crine regulator of AMPK and strengthens the crosstalk between
AT and skeletal muscle. The involvement of AMPK in apelin-
mediated glucose uptake represents an attractive pathway
that could conceivably lead to new drug target for the treatment
of metabolic disorders. The contribution of apelin should yield




Animals were handled in accordance with the principles and guidelines estab-
lished by the National Institute of Medical Research. C57Bl6/J WT and
eNOS/ mice were obtained from Charles River Laboratory (l’Arbresle
France). Mice deficient in AMPK activity (DN AMPK) were kindly provided by
the laboratory of Pr. Birnbaum (University of Pennsylvania Medical School
Philadelphia, USA). Mice were housed conventionally in a constant tempera-
ture (20C–22C) and humidity (50%–60%) animal room, with a 12/12 hr
light/dark cycle and free access to food and water. Injections and experiments
were performed in 13- to 15-week-old males. A group of male mice was fed
a HF containing 20% protein, 35% carbohydrate, and 45% fat (SAFE; Augy
France). HF-fed mice were followed at regular with measure of body weigh
and blood parameters (glucose, insulin) until they were obese and insulin resis-
tant (30–35 weeks old).
In Vivo Injection of Apelin
A catheter was indwelled into the femoral vein under anesthesia, sealed under
the back skin, and glued on the top of the skull. The mice were housed individ-
ually and allowed to recover for 3–4 days. On the day of the experiment the
mice were 6 hr fasted. Conscious mice were then injected with either apelin-
13 or PBS. Apelin (Bachem, UK) was injected as a bolus (100 ml/2 min) for gly-
cemia measurements.
Oral Glucose Tolerance Test
Six-hour-fasted mice were injected with apelin-13 (200 pmol/kg) or PBS 30 min
before oral glucose (3 g/kg) load. Blood was collected from the tail vein at 30etabolism 8, 437–445, November 5, 2008 ª2008 Elsevier Inc. 441
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Apelin Stimulates Glucose Utilization0, 15, 30, 60, 90, and 120 min and glycemia measured with a gluco-meter
(Accu-check Actine, Roche). Blood was also collected 30 min before glucose
load and during OGTT for plasma insulin and apelin concentrations.
Figure 3. Involvement of AMPK and Akt in Apelin-Induced Glucose Transport in Soleus Muscle
(A) Representative blot of in vitro time-course study of AMPK and ACC phosphorylation in soleus muscles by apelin (1 mM) and dose response (incubation time
with apelin: 20 min). Two millimolar 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) for 1 hr was used as a positive control. The graph shows the
quantified data; n = 3–4; *p < 0.05, **p < 0.01.
(B) In vivo AMPK and ACC phosphorylation in soleus muscle 20 min after an i.v. injection of 200 pmol/kg apelin or PBS (control) in 6-hr-fasted mice.
(C) Effect of 20 mM C compound on AMPK phosphorylation (top) and glucose transport (bottom) stimulated by apelin in isolated soleus muscle. Values are the
mean ± SEM, n = 5. *p < 0.05 versus basal and p < 0.05 versus apelin.
(D) Measure of tissue glucose utilization during an euglycemic-hyperinsulinemic clamp in apelin- (black bars) and saline-infused (white bars) DN-AMPK mice and
in apelin- (gray bars) and saline-infused (hatched bars) WT mice. The results are the mean ± SEM of 3–6 mice per group and per tissue. *p < 0.05, **p < 0.01.
(E) Representative blot of in vitro time-course study of Akt phosphorylation in soleus muscles by apelin (1 mM) and dose response (incubation time with apelin:
30 min). Insulin (100 nM) for 1 hr in time-course study or 30 min in the dose response was used as a positive control. The graphs show the quantified data, n = 3–4.
*p < 0.05.
(F) Effect of 25 mM LY294002 on Akt phosphorylation (top) and glucose transport (bottom) stimulated by apelin or insulin in isolated soleus muscle. Values are the
mean ± SEM, n = 3–4. *p < 0.05 versus basal and p < 0.05 versus apelin or insulin.
(G) Left: Akt and eNOS phosphorylation in isolated soleus muscle of WT and DN-AMPK mice incubated without (C) or with 10 nM apelin (A). The graph shows the
quantified data n = 3 of Akt (black bars) and eNOS (gray bars). Middle: effect of 25 mM LY294002 on AMPK and Akt phosphorylation in soleus muscle of WT mice in
the presence or not of 10 nM apelin or 100 nM insulin (incubation time: 30 min). The graph shows the quantified data, n = 3. *p < 0.05 versus control. Right: In vivo
AMPK and Akt phosphorylation in soleus muscle, 20 min after an i.v. injection of 200 pmol/kg apelin or PBS (control), in 6-hr-fasted eNOS/ mice.
Figure 4. Apelin Improves Glucose Toler-
ance and Glucose Utilization in HF-Fed
Insulin-Resistant Mice
(A) OGTT performed in 6-hr fasted insulin-resistant
mice i.v. injected with PBS (white square) or
200 pmol/kg apelin (black squares). The results
are the mean ± SEM of six mice per group.
*p < 0.05.
(B) Basal glucose TO in control (white bars) and
apelin-infused (75 pmol/kg/min) mice (black
bars). The results are the mean ± SEM of six
mice per group. *p < 0.05.
(C) GIR during an euglycemic-hyperinsulinemic
clamp in chow-fed and HF-fed mice infused with
saline (white bars) or apelin (75 pmol/kg/min)
(black bars). The results are the mean ± SEM
of six mice per group. *p < 0.05 versus saline
p < 0.05 versus chow-fed mice.
(D) Tissue glucose utilization during an euglyce-
mic-hyperinsulinemic clamp in saline- (white
bars) and apelin-infused (75 pmol/kg/min) (black
bars) mice. The results are the mean ± SEM of
five mice per group and per tissue. *p < 0.05 ver-
sus saline.
Glucose Turnover Studies
Whole-body glucose utilization rate was deter-
mined in basal and in hyperinsulinemic euglycemic
conditions in 6-hr-fasted mice. In basal state,
HPLC purified D-[3H]-glucose (Perkin Elmer; Bos-
ton, MA) was continuously infused in the femoral
vein at a rate of 10 mCi/kg/min for 3 hr. Under hy-
perinsulinemic conditions, insulin was infused at
a rate of 18 mU/kg/min for 3 hr. Apelin-13 was con-
tinuously infused either in basal or under hyperin-
sulinemic conditions at a rate of 75 pmol/kg/min
for 3 hr. To ensure a sufficient plasma D-[3H]-glu-
cose enrichment the tracer was infused at
30 mCi/kg/min. Plasma glucose concentrations
and D-[3H]-glucose-specific activity were deter-
mined in 5 ml of blood sampled as previously
described (Perrin et al., 2004). The whole-body
glycolytic flux was calculated from the [3H2O] ac-
cumulated in the plasma during the last 60 min of
the infusions. The whole-body glycogen synthesis rate was calculated by sub-
tracting the glycolytic flux from the glucose TO rate as previously described
(Perrin et al., 2004).Cell Metabolism 8, 437–445, November 5, 2008 ª2008 Elsevier Inc. 443
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To determine the insulin and apelin-stimulated glucose utilization in tissues,
a flash of intravenous injection of 50 mCi 2-deoxy-D-[3H] glucose (D-[3H]-
2DG) (NEN LifeScience) was performed in the femoral vein 60 min before the
end of the clamp. Plasma D-[3H]-2DG disappearance and glucose concentra-
tion were determined in 5 ml blood sampled from the tail vein at 0, 5, 10, 15, 20,
25, 30, 45, and 60 min after injection. Different tissues were dissected out and
treated as previously described (Kamohara et al., 1997).
Glucose Transport in Soleus Muscle
Muscles were isolated and preincubated for 10 min in Krebs-Henseleit (KH)
buffer, pH 7.4, containing BSA (2 mg/ml), 2 mM sodium pyruvate, and
20 mM HEPES. Muscles were then incubated for 45 min in the absence or
the presence of insulin and/or apelin-13. For glucose transport, muscles
were transferred in another vial containing KH medium supplemented with
D-2DG (0, 1 mM) and D-[3H]-2DG (0.4 mCi/ml) for 10 min. Muscles were then
washed for 1 hr in ice-cold iso-osmotic NaCl solution and dissolved in 1 M
NaOH during 1 hr. D-[3H]-2DG 6-phosphate and D-[3H]-2DG were differentially
precipitated by the use of zinc sulfate (0.3 M), baryum hydroxide (0.3 M) and
perchloric acid solutions (6%).
In order to determine the implication of AMPK and Akt in apelin-stimulated
glucose transport, 20 mM C Compound or 25 mM LY 294002, respectively,
were added during the preincubation and incubation of soleus muscle with
apelin. All the incubations were carried out at 37C under a 95% 02: 5%
CO2 atmosphere.
Western Blots
Muscle samples were lysed (precellys 24, Ozyme France) and loaded (50 mg
protein per lane) on a 10% SDS-PAGE gel and transferred to nitrocellulose
membrane (Schleicher-Schuell). Membranes were blotted with anti-phospho-
AMPKa-Thr172, anti-phospho-ACC-Ser79, anti-phospho-eNOS-Ser1177 or
anti-phospho-Akt-Ser473 antibodies (Cell Signaling Technology; Beverly,
MA). Membranes were then stripped and reprobed with specific antibodies
for total proteins. Immunoreactive proteins were detected using the ECL Plus
(GE Healthcare, UK) and quantified by Image Quant TL software (GE Healthcare
Bio-sciences, Sweden).
Real-Time PCR
Total RNAs (1 mg) were isolated from AT using RNeasy Lipid Tissue Kits
(QIAGEN, France) and from other tissues (muscle, heart, liver) using RNA
STAT (AMS Technology, UK). Total RNAs were reverse transcribed using ran-
dom hexamers and Superscript II reverse transcriptase (Invitrogen, UK). Real-
time PCR was performed as previously described (Boucher et al., 2005). The
sequences of the primers for apelin receptor were 50-GCTGTGCCTGTCA
TGGTGTT- 30 and 50-CACTGGATCTTGGTGCCATTT-30.
Plasma Samples
Serum insulin and apelin concentrations were measured using an ultrasensi-
tive mouse insulin ELISA (Mercodia; Uppsala, Sweden) and a nonselective
apelin-12 EIA kit (Phoenix Pharmaceuticals; Belmont, CA), respectively.
Statistical Analysis
Data are presented as means ± SEM. Analysis of differences between groups
was performed with Student’s t test, and p < 0.05 was considered to be signif-
icant.
SUPPLEMENTAL DATA
Supplemental Data include one figure and one table and can be found online at
http://www.cell.com/cellmetabolism/supplemental/S1550-4131(08)00321-5.
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